by increased demand for Neulasta. Combined sales of Neulasta and NEUPOGEN
in the U.S. were $856 million in the third quarter of 2008 versus $830
million in the third quarter of 2007, an increase of 3 percent primarily
reflecting an increase in demand for Neulasta. This increase in demand was
driven by an increase in the average net sales price, partially offset by a
decline in units sold, which we believe was primarily due to customer
stocking which occurred in the second quarter of 2008. Combined
international sales increased 24 percent to $336 million in the third
quarter of 2008 versus $270 million for the same quarter in the prior year.
This growth reflects changes in foreign exchange which positively impacted
third quarter 2008 combined international sales by approximately $33
million, as well as increased demand driven by the continued conversion
from NEUPOGEN to Neulasta. Excluding the impact of foreign exchange,
combined worldwide product sales increased 5 percent and international
product sales increased 12 percent.
Sales of Enbrel(R) (etanercept) increased 9 percent in the third
quarter to $893 million versus $821 million during the same period in 2007.
Sales growth was driven by higher demand due to increases in both average
net sales price and patients. ENBREL sales growth in the third quarter was
affected by share declines in the U.S. versus the third quarter of 2007 due
to increased competitive activity. However, sales growth continued in both
rheumatology and dermatology, and ENBREL continues to maintain a leading
position in both segments.
Worldwide sales of Sensipar(R) (cinacalcet) increased 32 percent to
$161 million in the third quarter of 2008 versus $122 million during the
third quarter of 2007. This growth was principally driven by demand,
primarily due to segment penetration.
Vectibix(R) (panitumumab) sales for the third quarter were unchanged
year over year at $41 million.
Operating Expense AnalysisPage: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Related biology technology :1
. CNS Response Announces Fiscal Third Quarter 2007 Results2
. Avitar Reports Third Quarter Financial Results for Fiscal 20073
. Martek to Announce Third Quarter 2007 Results on September 5, 20074
. Third Security, LLC Hires Two New Managing Directors5
. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings6
. ThirdBiotech Networking Group Launches7
. BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends8
. PPD Announces Third Quarter 2007 Earnings Release, Webcast and Conference Call9
. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results10
. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation11
. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers